

Special Issue

Biomarker in Glioblastoma

Message from the Guest Editors

Glioblastoma remains the most aggressive and lethal primary brain tumor. To date, no curative treatment is available despite a first line treatment composed of radiotherapy and chemotherapy and recent advances in oncology. The vast majority of immunotherapies and targeted therapies evaluated recently have failed to improve overall patient survival. To improve our patient management, it remains crucial to optimize tumor diagnosis, prognostic classification, and response and tolerance prediction using innovative biomarkers. This Special Issue aims to summarize some of most promising tissue, circulating, or radiological biomarkers in the field of newly diagnosed or recurrent glioblastomas.

Guest Editors

Dr. Emeline Tabouret

Department of Neuro-Oncology of Professor Olivier Chinot, La Timone University Hospital, 13005 Marseille, France

Dr. Mehdi Touat

Department of neuro-oncology, La Pitié-Salpêtrière Hospital, 75013 Paris, France

Deadline for manuscript submissions

closed (28 February 2022)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/62434

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)